EasySep™人中性粒细胞分选试剂盒

免疫磁珠负选未标记的人中性粒细胞

只有 %1 左

率先评论此产品

¥15,564.00

产品号 #（选择产品）

产品号 #17957_C

免疫磁珠负选未标记的人中性粒细胞

产品优势

操作简单、快捷，且无需分离柱
纯度高达99%
获得的活细胞无标记

产品组分包括

EasySep™人中性粒细胞分选试剂盒（产品号 #17957）

EasySep™人中性粒细胞分选抗体混合物，1 mL
EasySep™ Dextran RapidSpheres™磁珠，1 mL

RoboSep™ 人中性粒细胞分离试剂盒（含过滤吸头）（产品号 #17957RF）

EasySep™人中性粒细胞分选抗体混合物，1 mL
EasySep™ Dextran RapidSpheres™磁珠，1 mL
RoboSep™ 缓冲液（产品号 #20104）
RoboSep™ 过滤吸头（产品号 #20125）

立即询价

总览

使用EasySep™人中性粒细胞分离试剂盒，可轻松高效地从新鲜人外周血白细胞样本中通过免疫磁珠负选获得高纯度人中性粒细胞。EasySep™技术结合单克隆抗体的特异性和无柱磁分选系统的简便性，已在发表的研究中广泛应用超过20年。

在该EasySep™负选流程中，非目标细胞被抗体复合物与磁珠标记。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的中性粒细胞分离，接着简单地将目的细胞倾倒或吸取至一个新的试管中。磁珠分选最快仅需14分钟，目标中性粒细胞即可用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。本分离试剂盒兼容经HetaSep™（产品号 #07906）沉降法或红细胞裂解法处理的细胞样本。

该产品可替代EasySep™人中性粒细胞富集试剂盒 (产品号 #19257) 以进行更快地细胞分选。

了解更多关于免疫磁珠EasySep™技术的工作原理，或如何通过RoboSep™实现免疫磁珠细胞分选全自动化。亦可选择即用型、符合伦理来源的人外周血中性粒细胞冻存产品。探索更多为您实验流程优化的其它产品，包括培养基、补充剂、抗体等。

实验数据

Figure 1. Typical EasySep™ Human Neutrophil Isolation Profile

Starting with whole blood prepared using HetaSep™ or Lymphoprep™ with RBC lysis, the neutrophil content (CD45+CD16+CD66b+) of the isolated fraction typically ranges from 98.7 ± 0.9% (mean ± SD). In the above example, the purities of the start and final isolated fractions are 52.0% and 99.0%, respectively.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

文献 (11)

Circulating CD137⁺Treg cells and LOX-1⁺PMN-MDSCs as biomarkers of immunotherapy resistance in (R/M) HNSCC patients A. Asquino et al. Journal of Experimental & Clinical Cancer Research : CR 2025 Dec

Abstract

Background: Recurrent/metastatic head and neck squamous cell carcinoma ((R/M) HNSCC) represents one of the most aggressive and immunosuppressive cancers. Despite the introduction of immune checkpoint inhibitors (ICIs), only a limited number of patients obtain long-term benefits. In (R/M) HNSCC patients, the antitumor immune response is defective, conferring resistance and promoting tumor progression. Therefore, the identification of novel biomarkers for superior clinical outcomes and easily accessible in standard clinical settings is still an unmet clinical need. Methods: Blood liquid biopsies obtained from (R/M) HNSCC patients undergoing pembrolizumab therapy (monotherapy or in combination with chemotherapy) were analyzed by flow cytometry to evaluate the levels of circulating immunosuppressive regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs), at baseline and during therapy. Correlations between these immunosuppressive immune cell subsets and clinical parameters (clinical response rate, progression-free survival (PFS), overall survival (OS) and performance status (PS)) were performed. Results: Univariate analysis showed that before therapy, higher circulating levels of both CD137⁺Tregs and LOX-1⁺PMN-MDSCs, identified patients with significantly worse survival. Furthermore, CD137⁺Tregs resulted also positively correlated with worse PS, while high levels of LOX-1⁺PMN-MDSCs negatively affected response to pembrolizumab, with a significant increase in non-responsive patients during therapy. Interestingly, both CD137⁺Tregs as well as LOX-1⁺PMN-MDSCs exerted a higher immunosuppression on T cell proliferation than CD137−Tregs and LOX-1⁻PMN-MDSCs, respectively. Multivariate analysis revealed that the circulating LOX-1⁺PMN-MDSC subset resulted as an independent prognostic factor for survival by multivariate analysis, as confirmed in an independent validation cohort. Conclusions: The levels of blood circulating LOX-1⁺PMN-MDSCs may be proposed as non-invasive biomarkers to predict clinical outcomes of (R/M) HNSCC patients developing resistance to immunotherapy, improving patient selection and suggesting novel personalized therapies.

View publication

Bacterial biofilm-derived H-NS protein acts as a defense against Neutrophil Extracellular Traps (NETs) NPJ Biofilms and Microbiomes 2025 Apr

Abstract

Extracellular DNA (eDNA) is crucial for the structural integrity of bacterial biofilms as they undergo transformation from B-DNA to Z-DNA as the biofilm matures. This transition to Z-DNA increases biofilm rigidity and prevents binding by canonical B-DNA-binding proteins, including nucleases. One of the primary defenses against bacterial infections are Neutrophil Extracellular Traps (NETs), wherein neutrophils release their own eDNA to trap and kill bacteria. Here we show that H-NS, a bacterial nucleoid associated protein (NAP) that is also released during biofilm development, is able to incapacitate NETs. Indeed, when exposed to human derived neutrophils, H-NS prevented the formation of NETs and lead to NET eDNA retraction in previously formed NETs. NETs that were exposed to H-NS also lost their ability to kill free-living bacteria which made H-NS an attractive therapeutic candidate for the control of NET-related human diseases. A model of H-NS release from biofilms and NET incapacitation is discussed.

View publication

Neutrophil-derived migrasomes are an essential part of the coagulation system Nature Cell Biology 2024 Jul

Abstract

Migrasomes are organelles that are generated by migrating cells. Here we report the key role of neutrophil-derived migrasomes in haemostasis. We found that a large number of neutrophil-derived migrasomes exist in the blood of mice and humans. Compared with neutrophil cell bodies and platelets, these migrasomes adsorb and enrich coagulation factors on the surface. Moreover, they are highly enriched with adhesion molecules, which enable them to preferentially accumulate at sites of injury, where they trigger platelet activation and clot formation. Depletion of neutrophils, or genetic reduction of the number of these migrasomes, significantly decreases platelet plug formation and impairs coagulation. These defects can be rescued by intravenous injection of purified neutrophil-derived migrasomes. Our study reveals neutrophil-derived migrasomes as a previously unrecognized essential component of the haemostasis system, which may shed light on the cause of various coagulation disorders and open therapeutic possibilities. Jiang et al. document an abundance of neutrophil-derived migrasomes in the blood of mice and humans and show that migrasomes are enriched in coagulation factors, accumulate at sites of injury and trigger platelet activation and clot formation.

View publication

View All Publications

更多信息

更多信息
物种	人类
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • EasyPlate™ EasySep™ Magnet (Catalog #18102) • RoboSep™-S (Catalog #21000)
样本来源	PMNC, 全血
Selection Method	Negative

EasySep™人中性粒细胞分选试剂盒

产品号 #17957

产品号 #17957RF

产品号 #（选择产品）

产品号 #17957_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

EasySep™人中性粒细胞分选试剂盒

产品号 #17957

产品号 #17957RF

产品号 #（选择产品）

产品号 #17957_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

应用领域

相关材料与文献

技术资料 (10)

文献 (11)

Abstract

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台